{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:46:30Z","timestamp":1790145990839,"version":"4.0.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["2021S022"],"award-info":[{"award-number":["2021S022"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10557-023-07453-0","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T07:01:19Z","timestamp":1682924479000},"page":"757-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information"],"prefix":"10.1007","volume":"38","author":[{"given":"Fran\u00e7ois","family":"Boujonnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-9107","authenticated-orcid":false,"given":"Lucie-Marie","family":"Scailteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"7453_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med."},{"key":"7453_CR2","unstructured":"European Medicines Agency. Zytiga. EPAR - Public assessment report. 2011. [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zytiga-epar-public-assessment-report_en.pdf"},{"key":"7453_CR3","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/cancers14071792","volume":"14","author":"C Cattrini","year":"2022","unstructured":"Cattrini C, Caffo O, De Giorgi U, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers. 2022;14:1792.","journal-title":"Cancers."},{"key":"7453_CR4","unstructured":"European Medicines Agency. Erleada. EPAR - Public assessment report (Procedure No. EMEA\/H\/C\/004452\/0000). [Internet]. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/erleada-epar-public-assessment-report_en.pdf"},{"key":"7453_CR5","unstructured":"European Medicines Agency. Nubeqa. EPAR - Public assessment report. [Internet]. 2020 Apr. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/nubeqa-epar-public-assessment-report_en.pdf"},{"key":"7453_CR6","unstructured":"European Medicines Agency. Xtandi. EPAR - Public assessment report. 2013 [Internet].Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/xtandi-epar-public-assessment-report_en.pdf"},{"key":"7453_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/acs.chemrestox.9b00247","volume":"33","author":"C Ji","year":"2020","unstructured":"Ji C, Guha M, Zhu X, et al. Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol. 2020;33:211\u201322.","journal-title":"Chem Res Toxicol."},{"key":"7453_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol."},{"key":"7453_CR9","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","volume":"55","author":"GE Benoist","year":"2016","unstructured":"Benoist GE, Hendriks RJ, Mulders PFA, Gerritsen WR, Somford DM, Schalken JA, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55:1369\u201380.","journal-title":"Clin Pharmacokinet."},{"key":"7453_CR10","unstructured":"European Medicines Agency. Zytiga. EPAR - Public assessment report. 2017, [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/zytiga-h-c-2321-ii-0047-epar-assessment-report-variation_en.pdf"},{"key":"7453_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","volume":"14","author":"N Shore","year":"2019","unstructured":"Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019;14:527\u201339.","journal-title":"Target Oncol."},{"key":"7453_CR12","unstructured":"US FDA. Prescribing information: Nubeqa\u00ae (darolutamide), 2022, [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212099s002lbl.pdf"},{"key":"7453_CR13","unstructured":"European Medicines Agency. Erleada. EPAR - Public assessment report (Procedure No. EMEA\/H\/C\/004452\/II\/0001). [Internet]. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/erleada-h-c-4452-ii-0001-epar-assessment-report-variation_en-0.pdf"},{"key":"7453_CR14","volume-title":"Prescribing information: Erleada\u00ae (apalutamide) [Internet]","author":"US FDA","year":"2022","unstructured":"US FDA. Prescribing information: Erleada\u00ae (apalutamide), [Internet].\u00a02022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210951s009s010lbl.pdf"},{"key":"7453_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","volume":"59","author":"I Duran","year":"2020","unstructured":"Duran I, Carles J, Bulat I, et al. Pharmacokinetic drug\u2013drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer. Clin Pharmacokinet. 2020;59:1135\u201348.","journal-title":"Clin Pharmacokinet."},{"key":"7453_CR16","unstructured":"European Medicines Agency. Xtandi. EPAR - Public assessment report. [Internet]. 2021 Feb. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/xtandi-h-c-2639-ii-0047-g-epar-assessment-report-variation_en.pdf"},{"key":"7453_CR17","volume-title":"PRAC recommendations on signals [Internet]","author":"Pharmacovigilance Risk Assessment Committee","year":"2020","unstructured":"Pharmacovigilance Risk Assessment Committee. PRAC recommendations on signals [Internet]. 2020 Available from: https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-13-16-january-2020-prac-meeting_en-0.pdf"},{"key":"7453_CR18","unstructured":"US FDA. Prescribing information: Xtandi (enzalutamide), 2022, [Internet]. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203415s019,213674s006lbl.pdf"},{"key":"7453_CR19","unstructured":"US FDA. Prescribing information: Zytiga (abiraterone), 2021, [Internet]. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202379s035lbl.pdf"},{"key":"7453_CR20","unstructured":"European Medicines Agency. Xtandi. EPAR - Procedural steps taken and scientific information after the authorisation \u2013 2022, 2022, [Internet]. 2022 Jun. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/xtandi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf"},{"key":"7453_CR21","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","volume":"94","author":"J Hakkola","year":"2020","unstructured":"Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 2020;94:3671\u2013722.","journal-title":"Arch Toxicol."},{"key":"7453_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/17425255.2021.2027908","volume":"17","author":"J Vicente-Valor","year":"2021","unstructured":"Vicente-Valor J, Escudero-Vilaplana V, Collado-Borrell R, et al. Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice. Expert Opin Drug Metab Toxicol. 2021;17:1467\u201373.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"7453_CR23","first-page":"1","volume":"0","author":"D Conde-Est\u00e9vez","year":"2022","unstructured":"Conde-Est\u00e9vez D, Henr\u00edquez I, Mu\u00f1oz-Rodr\u00edguez J, Rodriguez-Vida A. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug\u2013drug interactions. Expert Opin Drug Metab Toxicol Taylor & Francis. 2022;0:1\u201313.","journal-title":"Expert Opin Drug Metab Toxicol Taylor & Francis."},{"key":"7453_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.nec.2018.06.003","volume":"29","author":"TA DeWald","year":"2018","unstructured":"DeWald TA, Washam JB, Becker RC. Anticoagulants: pharmacokinetics, mechanisms of action, and indications. Neurosurg Clin N Am. 2018;29:503\u201315.","journal-title":"Neurosurg Clin N Am."},{"key":"7453_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","volume":"70","author":"C Patrono","year":"2017","unstructured":"Patrono C, Morais J, Baigent C, et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017;70:1760\u201376.","journal-title":"J Am Coll Cardiol."},{"key":"7453_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/aje\/kwaa190","volume":"190","author":"L-M Scailteux","year":"2021","unstructured":"Scailteux L-M, Campillo-Gimenez B, Kerbrat S, et al. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR Cohort). Am J Epidemiol. 2021;190:413\u201322.","journal-title":"Am J Epidemiol."},{"key":"7453_CR27","unstructured":"IBM Watson Health (Healthcare) [Internet]. Greenwood Village, Colorado, USA: IBM Watson Health; Available from: https:\/\/www.micromedexsolutions.com\/"},{"key":"7453_CR28","unstructured":"Sweetman S (Ed). Martindale: The Complete Drug Reference. London: Pharmaceutical Press. (electronic version), IBM Watson Health (Healthcare), Greenwood Village, Colorado, USA. Available at: https:\/\/www.micromedexsolutions.com\/"},{"key":"7453_CR29","unstructured":"Quantitative prediction of drug drug interaction-DDI-Predictor Academic version [Internet]. 2022 [cited 2022 May 28]. Available from: https:\/\/www.ddi-predictor.org\/"},{"key":"7453_CR30","unstructured":"Centre D\u2019informations. Th\u00e9rapeutique Et De Pharmacovigilance. In: Carte dynamique des interactions medicamenteuses et CYP [Internet]. 2020 Mar. Available from: https:\/\/www.hug.ch\/sites\/interhug\/files\/structures\/pharmacologie_et_toxicologie_cliniques\/images\/carte_des_cytochromes_2020.pdf. Accessed March 16, 2022."},{"key":"7453_CR31","unstructured":"Agence Nationale De S\u00e9curit\u00e9 Du M\u00e9dicament Et Des Produits De Sant\u00e9. Thesaurus des interactions medicamenteuses [Internet]. 2020 Available from: https:\/\/ansm.sante.fr\/documents\/reference\/thesaurus-des-interactions-medicamenteuses-1. Accessed May 25, 2022."},{"key":"7453_CR32","first-page":"ehac244","volume":"2022","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;2022:ehac244.","journal-title":"Eur Heart J."},{"key":"7453_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/14740338.2020.1781089","volume":"19","author":"V Escudero-Vilaplana","year":"2020","unstructured":"Escudero-Vilaplana V, Collado-Borrell R, Hoyo-Mu\u00f1oz A, et al. Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice. Expert Opin Drug Saf. 2020;19:1041\u20138.","journal-title":"Expert Opin Drug Saf."},{"key":"7453_CR34","unstructured":"European Medicines Agency. Erleada, 2022, EPAR - Summary of product characteristics. [Internet]. 2022 Aug. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf"},{"key":"7453_CR35","unstructured":"European Medicines Agency. Xtandi. EPAR - Summary of product characteristics. [Internet]. 2022 Jun. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf"},{"key":"7453_CR36","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1124\/dmd.116.070672","volume":"44","author":"J Monbaliu","year":"2016","unstructured":"Monbaliu J, Gonzalez M, Bernard A, et al. In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity. Drug Metab Dispos American Society for Pharmacology and Experimental Therapeutics. 2016;44:1682\u201391.","journal-title":"Drug Metab Dispos American Society for Pharmacology and Experimental Therapeutics."},{"key":"7453_CR37","unstructured":"European Medicines Agency. Nubeqa, 2022. EPAR - Summary of product characteristics. [Internet]. 2022 Apr. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nubeqa-epar-product-information_en.pdf"},{"key":"7453_CR38","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"C Zurth","year":"2019","unstructured":"Zurth C, Koskinen M, Fricke R, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44:747\u201359.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"7453_CR39","first-page":"445","volume":"12","author":"R Potdar","year":"2022","unstructured":"Potdar R, Gartrell BA, Given R, et al. Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies. Am J Cancer Res. 2022;12:445\u201350.","journal-title":"Am J Cancer Res."},{"key":"7453_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/cts.13229","volume":"15","author":"S Poondru","year":"2022","unstructured":"Poondru S, Ghicavii V, Khosravan R, et al. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022;15:1131\u201342.","journal-title":"Clin Transl Sci."},{"key":"7453_CR41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1517\/17425255.2010.519334","volume":"6","author":"SC Laizure","year":"2010","unstructured":"Laizure SC, Parker RB. A comparison of the metabolism of clopidogrel and prasugrel. Expert Opin Drug Metab Toxicol Taylor & Francis. 2010;6:1417\u201324.","journal-title":"Expert Opin Drug Metab Toxicol Taylor & Francis."},{"key":"7453_CR42","first-page":"171","volume":"8","author":"FC Militaru","year":"2015","unstructured":"Militaru FC, Vesa SC, Pop TR, Buzoianu AD. Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015;8:171\u20135.","journal-title":"J Med Life."},{"key":"7453_CR43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40264-016-0443-8","volume":"39","author":"JL Fitzgerald","year":"2016","unstructured":"Fitzgerald JL, Howes LG. Drug interactions of direct-acting oral anticoagulants. Drug Saf. 2016;39:841\u20135.","journal-title":"Drug Saf."},{"key":"7453_CR44","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-017-3291-z","volume":"79","author":"C Bonnet","year":"2017","unstructured":"Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, et al. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer Chemother Pharmacol. 2017;79:1051\u20135.","journal-title":"Cancer Chemother Pharmacol."},{"key":"7453_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17425255.2022.2122812","volume":"18","author":"D Conde-Est\u00e9vez","year":"2022","unstructured":"Conde-Est\u00e9vez D, Henr\u00edquez I, Mu\u00f1oz-Rodr\u00edguez J, Rodriguez-Vida A. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug\u2013drug interactions. Expert Opin Drug Metab Toxicol Taylor & Francis. 2022;18:601\u201313.","journal-title":"Expert Opin Drug Metab Toxicol Taylor & Francis."},{"key":"7453_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","volume":"39","author":"AK Morgans","year":"2021","unstructured":"Morgans AK, Shore N, Cope D, et al. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021;39:52\u201362.","journal-title":"Urol Oncol."},{"key":"7453_CR47","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1185\/03007990903018360","volume":"25","author":"NA Farid","year":"2009","unstructured":"Farid NA, Jakubowski JA, Payne CD, et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin. Taylor & Francis. 2009;25:1821\u20139.","journal-title":"Curr Med Res Opin. Taylor & Francis."},{"key":"7453_CR48","unstructured":"European Medicines Agency. Efient. EPAR - Summary of product characteristics. 2021, [Internet]. 2021 Dec. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/efient-epar-product-information_en.pdf"},{"key":"7453_CR49","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Compte rendu de la r\u00e9union du 27 septembre 2017. 2017; Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2017-10\/compte_rendu_ct_27092017.pdf"},{"key":"7453_CR50","unstructured":"Agence Nationale De S\u00e9curit\u00e9 Du M\u00e9dicament Et Des Produits De Sant\u00e9. Lettre aux professionnels de sant\u00e9. 2018; Available from: https:\/\/ansm.sante.fr\/uploads\/2021\/04\/23\/dhpc-avk-2018-11-30.pdf"},{"key":"7453_CR51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40256-015-0157-9","volume":"16","author":"B Vakkalagadda","year":"2016","unstructured":"Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16:119\u201327.","journal-title":"Am J Cardiovasc Drugs."},{"key":"7453_CR52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11239-019-01823-y","volume":"47","author":"JB Washam","year":"2019","unstructured":"Washam JB, Hohnloser SH, Lopes RD, et al. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019;47:345\u201352.","journal-title":"J Thromb Thrombolysis."},{"key":"7453_CR53","doi-asserted-by":"crossref","unstructured":"MacDougall C, Canonica T, Keh C, BA PP, Louie J. Systematic review of drug\u2013drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. Pharmacother J Hum Pharmacol Drug Ther. 2022; [Internet]. [cited 2022 Mar 16];n\/a. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/phar.2672","DOI":"10.1002\/phar.2672"},{"key":"7453_CR54","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54:1057\u201369.","journal-title":"Clin Pharmacokinet."},{"key":"7453_CR55","first-page":"806","volume":"16","author":"M Bernier","year":"2019","unstructured":"Bernier M, Lancrerot S-L, Rocher F, et al. Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. J Geriatr Cardiol JGC. 2019;16:806\u201311.","journal-title":"J Geriatr Cardiol JGC."},{"key":"7453_CR56","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021;110:1526\u201336.","journal-title":"Clin Pharmacol Ther."},{"key":"7453_CR57","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JOP.2017.022004","volume":"13","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Daughety MM, Olson SR, Beer TM, DeLoughery TG. Management of anticoagulation in patients with prostate cancer receiving enzalutamide. J Oncol Pract. 2017;13:720\u20137.","journal-title":"J Oncol Pract."},{"key":"7453_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","volume":"95","author":"CS Landefeld","year":"1993","unstructured":"Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315\u201328.","journal-title":"Am J Med."},{"key":"7453_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11239-011-0555-z","volume":"31","author":"A Lee","year":"2011","unstructured":"Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis. 2011;31:249\u201358.","journal-title":"J Thromb Thrombolysis."},{"key":"7453_CR60","doi-asserted-by":"publisher","first-page":"e0176967","DOI":"10.1371\/journal.pone.0176967","volume":"12","author":"S Bloemen","year":"2017","unstructured":"Bloemen S, Zwaveling S, Ten Cate H, Ten Cate-Hoek A, de Laat B. Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing. PLoS One. 2017;12:e0176967.","journal-title":"PLoS One."},{"key":"7453_CR61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","volume":"151","author":"BT Samuelson","year":"2017","unstructured":"Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2017;151:127\u201338.","journal-title":"Chest."},{"key":"7453_CR62","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1161\/CIRCULATIONAHA.106.675587","volume":"115","author":"PA Gurbel","year":"2007","unstructured":"Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation. 2007;115:3156\u201364.","journal-title":"Circulation."},{"key":"7453_CR63","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0149-2918(07)80081-6","volume":"29","author":"M Muszkat","year":"2007","unstructured":"Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther. 2007;29:427\u201337.","journal-title":"Clin Ther."},{"key":"7453_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1072-7515(01)01163-2","volume":"194","author":"AR Tabrizi","year":"2002","unstructured":"Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg. 2002;194:267\u201373.","journal-title":"J Am Coll Surg."},{"key":"7453_CR65","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913\u201358.","journal-title":"Clin Pharmacokinet."},{"key":"7453_CR66","first-page":"512","volume":"121","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circul Am Heart Assoc. 2010;121:512\u20138.","journal-title":"Circul Am Heart Assoc."},{"key":"7453_CR67","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16:809\u201322.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"7453_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3\u201311.","journal-title":"Pharmacol Res."},{"key":"7453_CR69","unstructured":"Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. J Clin Oncol [Internet]. American Society of. Clin Oncol. 2014; [cited 2022 Oct 28]; Available from: https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/JCO.2013.54.8347?role=tab"},{"key":"7453_CR70","unstructured":"Mottet N, Cornford P, Roderick CN, van den B, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Eur Assoc Urol [Internet]. 2022; Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf"},{"key":"7453_CR71","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/S1166-7087(20)30752-1","volume":"30","author":"F Rozet","year":"2020","unstructured":"Rozet F, Mongiat-Artus P, Hennequin C, et al. Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU \u2013 actualisation 2020\u20132022\u00a0: cancer de la prostate. Prog En Urol. 2020;30:S136\u2013251.","journal-title":"Prog En Urol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07453-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:35:16Z","timestamp":1721792116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07453-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7453"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07453-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"18 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have approved and consent to publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"None","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}}]}}